Alpine Immune Sciences Inc. (ALPN)

Name: Alpine Immune Sciences Inc. (ALPN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Alpine Immune Sciences Inc. (ALPN)

Stock Card

$64.97

$0.00 (0.00%)

As on 20-May-2024 09:30EDT

Market cap

$4,457 Mln

Revenue (TTM)

$57 Mln

P/E Ratio

P/B Ratio

12.9

Div. Yield

0 %

Alpine Immune Sciences (ALPN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 64.97 High: 64.97

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-13 Mln
ROE

-0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-124.3
Debt to Equity

0
Book Value

$--
EPS

$-0.7
Face value

--
Shares outstanding

68,597,504

10 Years Aggregate

CFO

$-248.18 Mln

EBITDA

$-335.14 Mln

Net Profit

$-324.34 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Alpine Immune Sciences (ALPN)	240.9	0.7	107.8	583.9	62.9	61.3	--
BSE Sensex^*	-8.5	1.9	1.3	-5.1	6.1	6.7	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 20-May-2024 | *As on 26-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
Alpine Immune Sciences (ALPN)	159.3	-46.9	9.9	228.1	4.3	-66.9	25.0
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Alpine Immune Sciences (ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The... company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated. Read more

Executive Chairman & CEO

Dr. Mitchell H. Gold M.D.
Executive Chairman & CEO

Dr. Mitchell H. Gold M.D.
Headquarters

Seattle, WA
Website

https://www.alpineimmunesciences.com

FAQs for Alpine Immune Sciences (ALPN)

What is the current share price of Alpine Immune Sciences Inc (ALPN) Today?

The share price of Alpine Immune Sciences Inc (ALPN) is $64.97 (NASDAQ) as of 20-May-2024 09:30 EDT. Alpine Immune Sciences Inc (ALPN) has given a return of 62.9% in the last 3 years.

What is the current PB & PE ratio of Alpine Immune Sciences Inc (ALPN)?

Since, TTM earnings of Alpine Immune Sciences Inc (ALPN) is negative, P/E ratio is not available.
The P/B ratio of Alpine Immune Sciences Inc (ALPN) is 12.87 times as on 05-Aug-2024, a 141 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-29.61	2.91
2022	-4.20	1.35
2021	-6.88	2.86
2020	-9.47	4.26
2019	-1.63	2.35

What is the 52 Week High and Low of Alpine Immune Sciences Inc (ALPN)?

The 52-week high and low of Alpine Immune Sciences Inc (ALPN) are Rs -- and Rs -- as of 27-Aug-2026.

What is the market cap of Alpine Immune Sciences Inc (ALPN)?

Alpine Immune Sciences Inc (ALPN) has a market capitalisation of $ 4,457 Mln as on 05-Aug-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Alpine Immune Sciences Inc (ALPN)?

Before investing in Alpine Immune Sciences Inc (ALPN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.